Johnson & Johnson (NYSE:JNJ) Shares Acquired by Rice Partnership LLC

Rice Partnership LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 12.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 53,655 shares of the company’s stock after buying an additional 5,868 shares during the period. Johnson & Johnson accounts for about 2.8% of Rice Partnership LLC’s investment portfolio, making the stock its 9th biggest holding. Rice Partnership LLC’s holdings in Johnson & Johnson were worth $8,765,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Morton Brown Family Wealth LLC lifted its holdings in shares of Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares in the last quarter. Goodman Advisory Group LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter worth $39,000. First Bank & Trust lifted its holdings in shares of Johnson & Johnson by 69.6% in the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after purchasing an additional 156 shares in the last quarter. Heritage Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter worth $84,000. Finally, Timber Creek Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 225.0% in the 3rd quarter. Timber Creek Capital Management LLC now owns 650 shares of the company’s stock worth $106,000 after purchasing an additional 450 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on JNJ. SVB Leerink dropped their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Atlantic Securities lowered their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 19th. Sanford C. Bernstein lowered their target price on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Morgan Stanley lowered their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 6th. Finally, Barclays initiated coverage on Johnson & Johnson in a research note on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $168.31 on Wednesday. The business has a 50-day moving average of $175.98 and a 200 day moving average of $171.06. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The firm has a market cap of $440.04 billion, a P/E ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.23 by $0.12. The business had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.13 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s payout ratio is presently 62.95%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Insiders sold 233,611 shares of company stock valued at $40,960,735 in the last quarter. 0.35% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.